S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Oncimmune Share Forecast, Price & News

GBX 87.50
0.00 (0.00%)
(As of 07/4/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
776 shs
Average Volume
52,250 shs
Market Capitalization
£60.79 million
P/E Ratio
Dividend Yield
Price Target

Oncimmune MarketRank™ Forecast

Analyst Rating
Short Interest
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.22 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter.

Oncimmune logo

About Oncimmune (LON:ONC) Stock

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

ONC Stock News Headlines

Oncimmune (LON:ONC) Hits New 12-Month Low at $86.20
Oncimmune receives 2022 Queen's Award for Enterprise
FTSE 100 ends the week higher as Wall Street also recovers
Oncimmune lands follow-on Covid study contract
Oncimmune Hldngs PLC : Grant of Options and PDMR Dealing
Oncimmune Hldngs PLC : ImmunoINSIGHTS commercial update
Oncimmune Hldngs PLC : PDMR Dealing
Oncimmune Hldngs PLC : Notice of Full Year results
See More Headlines

Industry, Sector and Symbol

Diagnostics & Research
Year Founded

Company Calendar

Last Earnings


Pretax Margin


Sales & Book Value

Annual Sales
£3.33 million
Cash Flow
GBX 4.39 per share
Book Value
GBX 1.80 per share


Free Float
Market Cap
£60.79 million
Not Optionable

Oncimmune Frequently Asked Questions

How has Oncimmune's stock price performed in 2022?

Oncimmune's stock was trading at GBX 175 at the beginning of 2022. Since then, ONC stock has decreased by 50.0% and is now trading at GBX 87.50.
View the best growth stocks for 2022 here

How were Oncimmune's earnings last quarter?

Oncimmune Holdings plc (LON:ONC) released its earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share for the quarter. The business earned $0.08 million during the quarter.
View Oncimmune's earnings history

Who are Oncimmune's key executives?

Oncimmune's management team includes the following people:
  • Dr. Adam Mark Hill Ph.D., CEO & Director (Age 42, Pay $439k)
  • Mr. Matthew Hall, Chief Financial Officer
  • Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Chief Scientific Officer
  • Ms. Cléa Rosenfeld, Head of Investor Relations
  • Mr. Ron Kirschner, Gen. Counsel & Company Sec.
  • Dr. James R. Jett M.D., Chief Medical Officer of US
  • Mr. Maarten Brusse, Chief Commercial Officer of Asia
  • Mr. Shane Smith, Sr. VP of Market Access & Reimbursement Oncimmune (Usa)
  • Mr. Cameron Barnard, Chief Bus. Officer
  • Mr. Andrew Millet BA, FCA, MBA, Exec. (Age 55)

What other stocks do shareholders of Oncimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), (APHA), (AQB), Axsome Therapeutics (AXSM), (BGSF), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST).

What is Oncimmune's stock symbol?

Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC."

How do I buy shares of Oncimmune?

Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Oncimmune's stock price today?

One share of ONC stock can currently be purchased for approximately GBX 87.50.

How much money does Oncimmune make?

Oncimmune (LON:ONC) has a market capitalization of £60.79 million and generates £3.33 million in revenue each year.

How many employees does Oncimmune have?

Oncimmune employs 52 workers across the globe.

How can I contact Oncimmune?

Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The official website for Oncimmune is oncimmune.com. The company can be reached via phone at +44-115-8231869.

This page (LON:ONC) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.